MLYS Mineralys Therapeutics, Inc.
Company Analysis
Latest News
Mineralys Therapeutics third quarter 2026 loss misses estimates as company prepares for December launch
Mineralys Therapeutics reported a wider-than-expected loss for the third quarter of 2026 as the company aggressively scales its commercial infrastructure....
Mineralys Therapeutics, Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
Wall Street expects Mineralys Therapeutics to report zero revenue and a consensus EPS loss of $0.55 for the third quarter, with the stock currently trading at...
Mineralys Terminates Licensing Agreement, Acquires Full IP Rights to Lorundrostat
Mineralys Therapeutics has terminated its licensing agreement with Tanabe Pharma Corporation and acquired full ownership of the intellectual property for its...
Mineralys Therapeutics Appoints Two New Members to Board of Directors
Mineralys Therapeutics, Inc. (MLYS) announced the appointment of Kristine Peterson and Lonnel Coats to its Board of Directors, effective October 19, 2026. The...
Steve Cohen's Point72 Exits Mineralys Therapeutics Ahead of Key FDA Decision
In a significant portfolio shift, Steve Cohen's Point72 Asset Management fully exited its position in Mineralys Therapeutics (MLYS) during the second quarter...
Deerfield Management Discloses New $106.8M Stake in Mineralys Therapeutics
In a new 13F filing, healthcare-focused investment firm Deerfield Management revealed it has established a significant position in Mineralys Therapeutics...